Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Locally Recurrent Breast Cancer”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Testing effectiveness (Phase 2)Study completedNCT00559507
What this trial is testing

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Who this might be right for
Estrogen Receptor-negative Breast CancerMale Breast CancerProgesterone Receptor-negative Breast Cancer+4 more
National Cancer Institute (NCI) 12
Large-scale testing (Phase 3)Looking for participantsNCT06081959
What this trial is testing

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445908
What this trial is testing

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer and HR+/HER2- BC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 175
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Early research (Phase 1)Study completedNCT00010023
What this trial is testing

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Cancer
NYU Langone Health
Testing effectiveness (Phase 2)Study completedNCT01427933
What this trial is testing

Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 141
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Not applicableStudy completedNCT00253708
What this trial is testing

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Cancer
Beth Israel Deaconess Medical Center 39
Early research (Phase 1)Ended earlyNCT03878524
What this trial is testing

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8Anemia+47 more
OHSU Knight Cancer Institute 2
Large-scale testing (Phase 3)Active Not RecruitingNCT07386938
What this trial is testing

The Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
R-Pharm 246
Testing effectiveness (Phase 2)Study completedNCT03383679
What this trial is testing

Study on Androgen Receptor and Triple Negative Breast Cancer

Who this might be right for
Breast Cancer FemaleTriple Negative and Androgen Receptor Positive
UNICANCER 94
Testing effectiveness (Phase 2)Looking for participantsNCT05564377
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Who this might be right for
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+12 more
National Cancer Institute (NCI) 2,900
Large-scale testing (Phase 3)Study completedNCT00703326
What this trial is testing

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 1,144
Large-scale testing (Phase 3)Looking for participantsNCT07461454
What this trial is testing

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 376
Large-scale testing (Phase 3)Looking for participantsNCT06841354
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Who this might be right for
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Early research (Phase 1)Study completedNCT03767335
What this trial is testing

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Menarini Group 62
Testing effectiveness (Phase 2)Study completedNCT02614794
What this trial is testing

Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen Inc. 612
Testing effectiveness (Phase 2)Looking for participantsNCT06042894
What this trial is testing

SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 58
Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing

Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939
What this trial is testing

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Who this might be right for
HER2-positive Breast Cancer
Fudan University 288
Load More Results